Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 1, 2007
- Applied Clinical Trials-03-01-2007
- Volume 0
- Issue 0
eShowcase: Liquent InSight v. 3.5
Dual-purpose package allows submission in both paper and electronic formats
Advertisement
Dual-purpose package allows submission in both paper and electronic formats
Thomson Scientific (Philadelphia, PA, and London, UK) recently released the latest version of its regulatory compliance tool, InSight Publisher version 3.5. The latest iteration enables pharmaceutical companies to create, manage, and publish regulatory submissions in both paper and electronic form using a single software application, potentially saving critical time in the drug development process.
Around the world, regulatory authorities increasingly prefer the electronic format, yet they still require a paper version. With Liquent InSight version 3.5, life science professionals can produce both from a single assembly, using the same thin-client application integrated with the rest of the InSight software suite. Since it is built on the same platform as InSight Manager, which offers registration management and submission tracking capabilities, the entire platform is highly adaptable to different organizational processes and designs.
Thomson Scientific, (215) 386-0100,
Articles in this issue
over 19 years ago
Europe's Pediatric Rules in Force—At Lastover 19 years ago
Pressure Mounts to Streamline Trialsover 19 years ago
Is Something Better than Nothing?over 19 years ago
Promoting Clinical Trials in Japanover 19 years ago
eShowcase: Business Services Dashboardover 19 years ago
eShowcase: Clin'Formover 19 years ago
The Critical Path Initiative Meets Medical Devicesover 19 years ago
Taking Computers into the Next Virtual Realmover 19 years ago
Blinded by Science with Adaptive Designsover 19 years ago
Increase Your Company's Value with EDMAdvertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5